DE2903558C2 - Verwendung von L-Carnitin - Google Patents

Verwendung von L-Carnitin

Info

Publication number
DE2903558C2
DE2903558C2 DE2903558A DE2903558A DE2903558C2 DE 2903558 C2 DE2903558 C2 DE 2903558C2 DE 2903558 A DE2903558 A DE 2903558A DE 2903558 A DE2903558 A DE 2903558A DE 2903558 C2 DE2903558 C2 DE 2903558C2
Authority
DE
Germany
Prior art keywords
carnitine
cholesterol
hdl
administration
ldl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE2903558A
Other languages
German (de)
English (en)
Other versions
DE2903558A1 (de
Inventor
Claudio Cavazza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT4790078A external-priority patent/IT1104165B/it
Priority claimed from IT4935378A external-priority patent/IT1156739B/it
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of DE2903558A1 publication Critical patent/DE2903558A1/de
Application granted granted Critical
Publication of DE2903558C2 publication Critical patent/DE2903558C2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE2903558A 1978-02-03 1979-01-31 Verwendung von L-Carnitin Expired - Lifetime DE2903558C2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT4790078A IT1104165B (it) 1978-02-03 1978-02-03 Nuova applicazione terapeutica della carnitina della acetil-carnitina e di altri derivati acilati della carnitina
IT4935378A IT1156739B (it) 1978-05-15 1978-05-15 Applicazione terapeutica della carnitina

Publications (2)

Publication Number Publication Date
DE2903558A1 DE2903558A1 (de) 1979-08-09
DE2903558C2 true DE2903558C2 (de) 1994-09-01

Family

ID=26329244

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2903558A Expired - Lifetime DE2903558C2 (de) 1978-02-03 1979-01-31 Verwendung von L-Carnitin

Country Status (6)

Country Link
US (1) US4255449A (cg-RX-API-DMAC7.html)
JP (1) JPS54113409A (cg-RX-API-DMAC7.html)
CH (1) CH640414A5 (cg-RX-API-DMAC7.html)
DE (1) DE2903558C2 (cg-RX-API-DMAC7.html)
GB (1) GB2013495A (cg-RX-API-DMAC7.html)
NL (1) NL7900871A (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1156741B (it) * 1978-05-15 1987-02-04 Sigma Tau Ind Farmaceuti Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi
DE2921852A1 (de) * 1979-05-29 1980-12-11 Fresenius Chem Pharm Ind Lipide senkendes mittel
IT1119853B (it) * 1979-09-21 1986-03-10 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente l-carnitina per il trattamento delle dislipidemie ed iperlipo proteinemie
IT1142934B (it) * 1981-11-06 1986-10-15 Sigma Tau Ind Farmaceuti Uso della carnitina e delle acilcarnitine inferiori nel trattamento terapeutico della patologia delle vene
IT1157238B (it) * 1982-10-29 1987-02-11 Sigma Tau Ind Farmaceuti Impiego di 1-carnitina per migliorare i paramenti biochimici e comportamentali dell'eta' senile
CH655005A5 (it) * 1983-02-16 1986-03-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5545412A (en) * 1985-01-07 1996-08-13 Syntex (U.S.A.) Inc. N-[1, (1-1)-dialkyloxy]-and N-[1, (1-1)-dialkenyloxy]-alk-1-yl-n,n,n-tetrasubstituted ammonium lipids and uses therefor
JPH0667833B2 (ja) * 1985-11-28 1994-08-31 雪印乳業株式会社 経腸栄養剤
JP2518636B2 (ja) * 1987-02-13 1996-07-24 雪印乳業株式会社 重症感染症及び広範囲熱症治療経腸栄養剤
IT1231944B (it) * 1989-05-05 1992-01-16 Sigma Tau Ind Farmaceuti Composizione farmaceutica per il trattamento di protozoosi, particolarmente della tripasonomiasi comprendente d-carnitina o un alcanoilderivato della d-carnitina
CA2018137C (en) * 1989-06-14 2000-01-11 Thomas Scholl L-carnitine magnesium citrate
US5073376A (en) * 1989-12-22 1991-12-17 Lonza Ltd. Preparations containing l-carnitine
JP2543382Y2 (ja) * 1991-10-22 1997-08-06 住友電装株式会社 フラットワイヤーハーネス
US6080428A (en) * 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
US6676967B1 (en) * 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6129930A (en) * 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
IT1276253B1 (it) 1995-12-15 1997-10-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o alcanoil l-carnitine per la prevenzione ed il trattamento di stati morbosi
IT1291127B1 (it) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica
IT1294227B1 (it) * 1997-08-01 1999-03-24 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l-carnitina e alcoli alifatici a lunga catena utile per la prevenzione
IT1306178B1 (it) * 1999-07-27 2001-05-30 Sigma Tau Ind Farmaceuti Uso della l-carnitina e dei suoi alcanoil derivati per la preparazionedi un medicamento utile nel trattamento del paziente affetto da
IT1307278B1 (it) * 1999-11-18 2001-10-30 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di disturbi dovutiad un alterato metabolismo dei lipidi, che comprende propionil
DE10128934A1 (de) * 2001-06-18 2003-02-06 Bernhard Sibbe Wirkstoffzusammensetzung zur Vorbeugung gegen Angina-Pectoris-Beschwerden
US20030194423A1 (en) 2002-04-15 2003-10-16 Mars, Inc. Composition for enhancing nutritional content of food
DE10331202A1 (de) 2003-07-10 2005-03-31 S.K. Enterprise Gmbh Verwendung von Molkenpermeat zur Behandlung des Metabolischen Syndroms
US8173618B2 (en) * 2003-07-25 2012-05-08 University Of Massachusetts Formulations for reducing neuronal degeneration
US20070072910A1 (en) * 2005-09-29 2007-03-29 Smith Michael L Compositions and methods for lowering plasma concentrations of low density lipoproteins in humans
US8003683B2 (en) 2005-11-11 2011-08-23 Signature R&D Holdings, Llc Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements
DE102006036285A1 (de) 2006-08-03 2008-02-07 "S.U.K." Beteiligungs Gmbh Fraktionen aus Molkepermeat und deren Verwendung zur Prävention und Therapie des Typ-2 Diabetes und des Metabolischen Syndroms
WO2008018877A1 (en) * 2006-08-11 2008-02-14 Ssv Therapeutics, Inc. Carnitine conjugates as dual prodrugs, methods of production and uses thereof
CN101573326B (zh) 2006-11-09 2013-05-01 三菱丽阳株式会社 甜菜碱的制造方法
US20080279967A1 (en) * 2007-05-10 2008-11-13 Marvin Heuer Composition and method for increasing the metabolism of free fatty acids and facilitating a favorable blood lipid
US20080279968A1 (en) * 2007-05-10 2008-11-13 Marvin Heuer Composition and method for inducing lipolysis and increasing the metabolism of free fatty acids
US8597640B2 (en) * 2007-10-31 2013-12-03 University Of Massachusetts Lowell Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging
EP2353596A1 (en) 2010-02-02 2011-08-10 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Combination composition, comprising as active ingredients L-carnitine or propionyl L-carnitine, for the prevention or treatment of chronic venous insufficiency
RS54100B1 (sr) 2011-05-03 2015-10-30 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Supstanca korisna za lečenje poremećaja metabolizma lipida

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1435916A (en) * 1972-05-11 1976-05-19 Beecham Group Ltd Pharmaceutical weight-reducing compositions
US3810994A (en) * 1972-06-01 1974-05-14 Ethyl Corp Method and composition for treating obesity
US3968241A (en) * 1972-11-06 1976-07-06 Defelice Stephen L Method of treating cardiac arrhythmias and of improving myocardial contractility and systolic rhythm with carnitive or a pharmaceutically acceptable salt thereof
US3830931A (en) * 1972-11-06 1974-08-20 Felice S De Carnitine and its use in the treatment of arrhythmia and impaired cardiac function
US4032641A (en) * 1976-06-09 1977-06-28 Tanabe Seiyaku Co., Ltd. Nicotinoyl carnitine derivatives

Also Published As

Publication number Publication date
US4255449A (en) 1981-03-10
JPS54113409A (en) 1979-09-05
CH640414A5 (it) 1984-01-13
DE2903558A1 (de) 1979-08-09
GB2013495A (en) 1979-08-15
NL7900871A (nl) 1979-08-07
JPS649287B2 (cg-RX-API-DMAC7.html) 1989-02-16

Similar Documents

Publication Publication Date Title
DE2903558C2 (de) Verwendung von L-Carnitin
DE2903579A1 (de) Verwendung von acetylcarnitin und anderen acylderivaten des carnitins zur behandlung der hyperlipoproteinaemie und hyperlimpidaemie sowie arzneimittel
DE69618158T2 (de) Pharmazeutische Zusammensetzung enthaltend ein Alkanoyl-L-Carnitin in Kombination mit einer polyungesättigten Fettsäure der Omega-3-Serie zur Verhütung und Behandlung von Störungen des Fettstoffwechsels
DE69629273T2 (de) Zusammensetzungen enthaltend Propionyl-L-Carnitine und Hydroxyzitronensäure oder Pantothensäure
DE60212786T2 (de) Verwendung mehrfach ungesättigter Fettsäuren zur primären Prävention kardiovaskulärer Ereignisse
EP0607231B1 (de) Verwendung einer emulsion, zur herstellung eines arzneimittels zur i.v.-verabreichung zur behandlung von hauterkrankungen
DE69826683T2 (de) Therapeutische zusammensetzungen, enthaltend amlopidin und atorvastatin
EP0637957B1 (de) Verwendung einer omega-3-fettsäuren enthaltenden emulsion zur herstellung eines parenteral zu verabreichenden arzneimittels zur behandlung von entzündlichen erkrankungen
DE69624699T2 (de) Hochdosiertes chromtripicolinat zur behandlung von typ-ii-diabetes
DE2911670A1 (de) Arzneimittel zur therapeutischen behandlung von peripheren vaskularen erkrankungen
DE69911441T2 (de) Verwendung von carnitinen und resveratrol zur herstellung einer zusammensetzung zur verhinderung oder behandlung von zerebralenerkrankungen verursacht durch alterung und verwendung neurotoxischer mittel
DE69328618T2 (de) Medikamente auf der Basis von Docosahexaensäure, als Plättchenaggregationshemmer und gegen cerebralen Mangel an Fettsäuren, und Verfahren zur Herstellung.
EP0282696B1 (de) Verwendung von Pyridoxin-Derivaten bei der Prophylaxe und Therapie von Hyperlipidämien und Atherosklerose
DE69733089T2 (de) Behandlung der osteoarthritis durch verabreichung von poly-n-acetyl-d-glucosamin
EP0456764B1 (de) Omega-3-fettsäurenhaltige fettemulsion zur endotrachealen applikation, ihre herstellung und anwendung
DE60015560T2 (de) Verwendung von aminosäure zur herstellung von arzneimitteln zur behandlung von insulinresistenz
AU1177595A (en) Butyric ester cyto-differentiating agents
DE69021304T2 (de) Vorbeugendes und therapeutisches Mittel gegen Hepatitis.
DE3726945A1 (de) L-carnitinderivate der valproinsaeure und diese enthaltende arzneimittel
DE3000139A1 (de) Die verwendung von glyzerinphosphorylderivaten in der therapie der dislipaemie, der hepatitis und vergleichgeeignete pharmazeutische kompositionen
DE3035494A1 (de) Carnitin enthaltendes arzneimittel zur behandlung von hyperlipidaemie und hyperlipoproteinaemie, sowie verwendung von carnitin zur herstellung eines solchen arzneimittels
DE60207442T2 (de) VERWENDUNG EINER KOMBINATIONSZUSAMMENSETZUNG BESTEHEND AUS PROPIONYL L-CARNITIN UND WEITEREn WIRKSTOFFEn ZUR BEHANDLUNG DER EREKTILEN DYSFUNKTION
DE2660486C2 (de) Verwendung von 2-Hydroxymethyl-3,4,5-trihydroxypiperidin als Arzneimittel
DE2445801A1 (de) Arzneimittel zur behandlung von diabetischer ketoacidose
DE68903448T2 (de) Pharmazeutische und/oder diaetetische zusammensetzungen mit gehalt an l-carnitin und l-lysin.

Legal Events

Date Code Title Description
8128 New person/name/address of the agent

Representative=s name: EITLE, W., DIPL.-ING. HOFFMANN, K., DIPL.-ING. DR.

8110 Request for examination paragraph 44
D2 Grant after examination
8364 No opposition during term of opposition